Who Owns Autobio Diagnostics Company?

Autobio Diagnostics Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Autobio Diagnostics?

Understanding a company's ownership is key to grasping its strategy and accountability. Autobio Diagnostics, a prominent player in China's in-vitro diagnostics market, went public on the Shanghai Stock Exchange on September 1, 2016. Founded in 1998 and headquartered in Zhengzhou, China, the company has a history of advancing healthcare solutions.

Autobio Diagnostics specializes in R&D, manufacturing, and marketing of IVD products, offering integrated solutions for clinical laboratories. Their portfolio includes immunoassay, microbiology, biochemistry, and molecular diagnostics, supporting disease diagnosis and health management. A look into their Autobio Diagnostics PESTEL Analysis can offer further insights into their market positioning.

As of August 18, 2025, Autobio Diagnostics holds a market capitalization of approximately RMB 23.79 billion. In 2024, the company reported revenues of RMB 4.471 billion and a net profit of RMB 1.19 billion. With a workforce of 5,773 employees, Autobio Diagnostics is a leading IVD manufacturer in China.

Autobio Diagnostics Co., Ltd. was established in 1998 in Zhengzhou, China. While specific individual founders and their precise equity splits at inception are not publicly detailed, the company's 'About Us' information confirms its founding year. The 'Zhang Family' is identified as a significant major shareholder, holding 13.12% of the company's shares as of recent data, which strongly suggests a foundational role and continued influence in the company's ownership.

Founding Entity

Autobio Diagnostics Co., Ltd. was established in 1998. The specific individuals who founded the company and their initial equity stakes are not publicly disclosed.

Key Family Shareholder

The Zhang Family is a significant shareholder, holding 13.12% of the company's shares. This indicates a substantial foundational ownership interest.

Primary Holding Company

Zhengzhou Autobio Co., Ltd., a subsidiary, holds a dominant 57.65% stake as of September 29, 2024. This suggests a consolidated ownership structure from early stages.

Leadership Roles

Zengli Yang serves as the legal representative and general manager. Yongjun Miao is the Chairman, both are key figures in the company's management.

Early Ownership Structure

The presence of Zhengzhou Autobio Co., Ltd. as a major shareholder suggests a primary holding company was likely established early to manage founding ownership interests.

Information Availability

Details regarding early ownership agreements, such as vesting schedules or buy-sell clauses, are not publicly available.

The Autobio Diagnostics ownership structure points to a significant influence from the Zhang Family, holding 13.12% of the company's shares. This family stake, combined with the substantial 57.65% ownership by Zhengzhou Autobio Co., Ltd. as of September 29, 2024, indicates a concentrated ownership, likely stemming from the company's founding in 1998. The leadership roles of Zengli Yang as legal representative and general manager, and Yongjun Miao as Chairman, are central to the company's operations and strategic direction. Understanding these key stakeholders is crucial for grasping the Autobio Diagnostics corporate structure and who controls its operations. While specific details about early agreements are not public, the current ownership pattern suggests a foundational consolidation of interests. This information is vital for anyone researching Autobio Diagnostics financial ownership information or its ownership history, and provides context for its position within the Competitors Landscape of Autobio Diagnostics.

Key Ownership Insights

The ownership of Autobio Diagnostics is significantly influenced by a major family shareholder and a primary holding company. This structure suggests a stable, though concentrated, ownership base.

• The Zhang Family holds 13.12% of the company's shares.
• Zhengzhou Autobio Co., Ltd. is the largest shareholder with 57.65% as of September 29, 2024.
• The company was founded in 1998 in Zhengzhou, China.
• Key management figures include Zengli Yang and Yongjun Miao.

Autobio Diagnostics SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Autobio Diagnostics Co., Ltd. transitioned to public ownership with its IPO on the Shanghai Stock Exchange on September 1, 2016, achieving a market capitalization of approximately RMB 8.82 billion at its debut. This event broadened its investor base, including significant institutional and individual participation.

The current ownership structure of Autobio Diagnostics is largely consolidated under its holding company, Zhengzhou Autobio Co., Ltd., which maintains a controlling stake of 57.65% as of September 29, 2024. The founding Zhang Family also retains a significant direct interest of 13.12%. A diverse group of institutional investors, including Zhong Geng Fund Management Co., Ltd. (2.39%), Hwabao WP Fund Management Co., Ltd. (1.315%), and Shanghai Minghe Investment Management Co. Ltd. (0.614%), alongside other entities like China Southern Asset Management Co., Ltd. and Hua Life Insurance Co., Ltd., contribute to the company's broad shareholder profile. This distribution of ownership influences the company's strategic direction and market presence within the in-vitro diagnostics sector, aligning with the insights discussed in the Target Market of Autobio Diagnostics article.

Key Ownership Dynamics

Autobio Diagnostics' ownership is primarily concentrated, with a significant majority held by its parent company. The public listing has introduced a layer of institutional investors, diversifying the shareholder base.

• Zhengzhou Autobio Co., Ltd. is the primary controlling entity.
• The Zhang Family maintains a substantial direct ownership stake.
• Institutional investors play a role in the company's shareholder structure.
• The IPO in 2016 marked a significant shift towards public ownership.

Autobio Diagnostics PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors for Autobio Diagnostics Co., Ltd. is structured to include both executive and independent members, reflecting a blend of operational leadership and external oversight. Key figures like Yongjun Miao, the Chairman, and Yaxun Zhang, the Vice Chairman, guide the board's strategic direction.

The voting power within Autobio Diagnostics Co., Ltd. is significantly influenced by its ownership structure. Zhengzhou Autobio Co., Ltd. holds a substantial majority stake of 57.65%, which translates directly into considerable control over corporate decisions and board appointments. This concentration of ownership means that the interests of Zhengzhou Autobio Co., Ltd., and by extension the 'Zhang Family' and leadership of Zhengzhou Autobio Co., Ltd., are paramount in the company's governance. While there are no public records indicating dual-class share structures or specific voting rights that deviate from standard common share ownership, the dominant shareholding ensures a strong, centralized decision-making authority. This robust ownership position has historically meant a stable governance framework, with no significant public challenges from activist investors or proxy battles impacting the company's direction. Understanding this ownership is key to understanding Autobio Diagnostics ownership.

Understanding Autobio Diagnostics Ownership

The control of Autobio Diagnostics Co., Ltd. is largely consolidated due to a significant majority shareholding. This structure impacts how the company is managed and its strategic decisions are made.

• Zhengzhou Autobio Co., Ltd. is the primary owner with 57.65% of shares.
• Executive directors often represent major shareholder interests.
• Independent directors provide objective oversight.
• The current structure suggests a stable management and ownership framework.
• This information is crucial for understanding Autobio Diagnostics stock ownership and who owns Autobio Diagnostics.

Autobio Diagnostics Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent activities indicate a dynamic shift in Autobio Diagnostics' ownership landscape, with a focus on shareholder value and strategic consolidation. The company's recent equity buyback and a planned 'cancellation repurchase' highlight efforts to bolster investor confidence and refine its ownership structure.

The controlling shareholder, likely Zhengzhou Autobio Co., Ltd., has reinforced its position by increasing its stake by 0.81% as of September 5, 2024. While direct acquisitions of Autobio have not been a major focus, the company has strategically invested in early-stage ventures, such as its July 31, 2024, investment in Renke Biotech. This move suggests a broader strategy of expanding into related fields and fostering potential partnerships within the diagnostics sector. The in-vitro diagnostics market is experiencing robust growth, with a projected CAGR of approximately 7% from 2023 to 2030, positioning Autobio favorably to leverage its research and development capabilities. The company's management has set an ambitious revenue target of ¥7 billion by 2025, underscoring its commitment to innovation and market expansion.

Shareholder Confidence Initiatives

The company's recent equity buyback, totaling approximately CNY 455.45 million, aims to enhance shareholder value. A further plan for cancellation repurchases between 250-500 million yuan signals a commitment to consolidating ownership and potentially increasing per-share value.

Strategic Investment and Growth Outlook

An early-stage venture capital investment in Renke Biotech on July 31, 2024, indicates a forward-looking strategy. This aligns with the company's goal to achieve a revenue target of ¥7 billion by 2025, capitalizing on the expanding diagnostics market.

Controlling Shareholder Reinforcement

The controlling shareholder's increase in holdings by 0.81% as of September 5, 2024, solidifies its dominant position. This move is significant for understanding who controls Autobio Diagnostics' operations and its overall corporate structure.

Market Position and Future Ambitions

The company is well-positioned within the in-vitro diagnostics market, projected to grow at a CAGR of around 7% through 2030. This growth trajectory supports the company's ambitious revenue goals, as detailed in its Brief History of Autobio Diagnostics.

Autobio Diagnostics Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔